I. Craig Henderson, MD

Education

Grinnell College, Grinnell, IA, A.B., 1963
Columbia University, College of Physicians & Surgeons, New York, NY, M.D., 1970

Professional Experience

• 1970-1972
  Intern and Resident in Medicine, Presbyterian Hospital, New York, NY
• 1972-1974
  Research Associate, Viral Leukemia and Lymphoma Branch, NCI, Bethesda
• 1974-1975
  Clinical Fellow in Medicine, Sydney Farber Cancer Inst., Harvard Medical School (HMS)
• 1975-1976
  Instructor of Medicine, Sydney Farber Cancer Inst., HMS
• 1976-1984
  Assistant Professor of Medicine, Dana-Farber Cancer Inst., HMS
• 1979-1992
  Founder and Director, Breast Evaluation Center, Dana-Farber Cancer Inst., Boston
• 1981-1982
  Consultant, Cancer Unit, World Health Organization, Geneva, Switzerland
• 1982-1996
  Breast Core Committee, Cancer and Acute Leukemia Group B (Chairman 1990-1995)
• 1983-1993
  Subcommittee on Antineoplastic and Immunosuppressive Drugs, Committee on Essential Drugs, World Health Organization (Chairman 1983)
• 1984-1992
  Associate Professor of Medicine, Dana-Farber Cancer Inst., HMS, Boston
• 1985-1993
  World Health Organization Expert Advisory Panel on Cancer, Geneva
• 1985-1995
  Early Breast Cancer Trialists Collaborative Group (Oxford Overview Group) (Chairman 1985-1995)
• 1987-1990
  United States Congressional Office of Technology Assessment: Working Group on Immuno-Augmentative Therapy
• 1988-1994
  National Task Force on Breast Cancer Control, American Cancer Society
• 1989-1992
  Member, Oncologic Drugs Advisory Committee, FDA (Chairman 1990-1992)
• 1991-1993
  Education Committee, American Society of Clinical Oncology
• 1992-1995
  Professor of Medicine, University of California San Francisco (UCSF)
• 1992-1995
  Chief, Division of Oncology, Moffitt-Long-Mt. Zion
• 1992-1995
  Assoc. Director for Clinical Oncology in Comprehensive Cancer Center, UCSF (Interim)
• 1992-1996
  Founder, PI, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
• 1996-present
  Steering Committee Member, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
• 1995-present
  Adjunct Professor of Medicine, University of California San Francisco
• 1995-1999
  CEO and Chairman, SEQUUS Pharmaceuticals, Menlo Park Ca.
• 1999-present
  Senior Consultant, Alza Corporation, Mountain View, Ca. (Director 1999-2001)
• 2000-present
  Institute of Medicine Committee on Technologies for the Early Detection of Breast Cancer (Vice Chairman)
• 2000-present
  Breast Cancer Research Council of the State of California
• 2001-present
  President and Director, Access Oncology, Inc., New York City, NY

Honors & Awards

• 1966
  Merck, Sharpe and Dohme International Fellow, Columbia University
• 1970
  Research Prize, Columbia University Medical Society
• 1988
  Fellow, American College of Physicians
• 1987
  Henrietta Banting Memorial Lecturer, Canada
• 1992
  General Motors Cancer Research Foundation Lecturer, The Royal Marsden
• 1992
  Bernard L. Schwartz Lecturer, Scripps Memorial Hospitals
• 1993
  British Oncological Association Lecturer, United Kingdom
• 1993
  Distinguished Alumnus Award, Grinnell College
• 1994
  Doctorate of Science, Grinnell College
• 1996
  Wendell Scott Lecture, American College of Radiology
• 1997
  Fellow, Royal College of Physicians (Edinburgh)
• 1999
  Outstanding Industry Leader in Medical Research, California Pacific Medical Center Research Institute
• 2000
  Millennium Award from Bristol-Myers Squibb Oncology and Susan G. Komen Breast Cancer Foundation

Selected Publications

1. Henderson IC. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127.
   View on PubMed
2. Henderson IC. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62.
   View on PubMed

View on UCSF Profiles